Media headlines about Humana (NYSE:HUM) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Humana earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave news articles about the insurance provider an impact score of 46.9570993084123 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the media headlines that may have impacted Accern’s rankings:

Shares of Humana (NYSE:HUM) opened at 246.90 on Friday. The firm has a market capitalization of $35.68 billion, a price-to-earnings ratio of 20.31 and a beta of 0.86. Humana has a 52 week low of $163.50 and a 52 week high of $259.76. The firm has a 50-day moving average price of $249.09 and a 200-day moving average price of $234.31.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share for the quarter, beating analysts’ consensus estimates of $3.08 by $0.41. Humana had a return on equity of 15.85% and a net margin of 3.37%. The business had revenue of $13.53 billion for the quarter, compared to the consensus estimate of $13.61 billion. During the same quarter in the previous year, the company posted $2.30 earnings per share. On average, equities analysts expect that Humana will post $11.55 earnings per share for the current fiscal year.

The company also recently announced a dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 29th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Thursday, September 28th. Humana’s dividend payout ratio (DPR) is currently 13.06%.

HUM has been the topic of several research reports. UBS AG reissued a “neutral” rating and issued a $250.00 target price (up previously from $237.00) on shares of Humana in a report on Wednesday, August 9th. Zacks Investment Research lowered Humana from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Cowen and Company reissued a “buy” rating and issued a $230.00 target price on shares of Humana in a report on Friday, July 14th. BidaskClub raised Humana from a “sell” rating to a “hold” rating in a report on Thursday, August 10th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $223.00 target price (up previously from $200.00) on shares of Humana in a report on Thursday, August 3rd. Nine analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $247.50.

COPYRIGHT VIOLATION NOTICE: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2017/10/07/humana-hum-given-media-impact-score-of-0-22.html.

In other Humana news, insider Elizabeth D. Bierbower sold 9,786 shares of the business’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $259.00, for a total value of $2,534,574.00. Following the transaction, the insider now owns 18,042 shares in the company, valued at $4,672,878. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider William Kevin Fleming sold 3,071 shares of the business’s stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $250.98, for a total value of $770,759.58. Following the completion of the transaction, the insider now owns 7,681 shares in the company, valued at approximately $1,927,777.38. The disclosure for this sale can be found here. Insiders sold 55,595 shares of company stock worth $14,133,706 in the last 90 days. Corporate insiders own 0.80% of the company’s stock.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Insider Buying and Selling by Quarter for Humana (NYSE:HUM)

Receive News & Stock Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related stocks with our FREE daily email newsletter.